Regulatory T-cell modulation by green tea in chronic lymphocytic leukemia

International Journal of Immunopathology and Pharmacology

Volumn 26, Issue 1, 2013, Pages 117-125

  D'Arena, G ^a   Simeon, V ^a   De Martino, L ^b   Statuto, T ^a   D'Auria, F ^a   Volpe, S ^c   Deaglio, S ^d   Maidecchi, A ^e   Mattoli, L ^e   Mercati, V ^e   Musto, P ^a   De Feo, Vincenzo ^b  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

^c S G MOSCATI HOSPITAL   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e ABOCA SpA Società Agricola   (Italy)

Author keywords

Green tea; Immune system; Rai stage 0; Tregs

Indexed keywords

GREEN TEA EXTRACT; TRANSFORMING GROWTH FACTOR BETA; ANTINEOPLASTIC AGENT; CAFFEINE; EPIGALLOCATECHIN GALLATE; INTERLEUKIN 10;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIETARY INTAKE; EPIGASTRIC PAIN; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOMODULATION; LYMPHOCYTE COUNT; LYMPHOCYTOSIS; MALE; METEORISM; PLANT LEAF; POWDER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; TACHYCARDIA; TEA; COHORT ANALYSIS; DRUG EFFECT; HUMAN CELL; IMMUNOREGULATION; MIDDLE AGED; RECOMMENDED DRUG DOSE; TREATMENT OUTCOME; VERY ELDERLY;

EID: 84881230358     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201302600111     Document Type: Article

References (31)

1. Cabrera C, Artacho R, Giménez R. Beneficial effects of green tea - A review. J Amer Coll Nutr 2006; 25:79-99. (Pubitemid 46939847)
2. Sharangi AB. Medicinal and therapeutic potentialities of tea (Camellia sinensis L) - A review. Food Res Int 2009; 42:529-35.
3. Singh BN, Shankar S, Srivastava RK. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol 2011; 82:1807-21.
4. Cooper R, Morré DJ, Morré DM. Medicinal benefits of green tea: Part I Review of noncancer health benefits. J Altern Complem Med 2005; 11:521-28. (Pubitemid 41001422)
5. Cooper R, Morré DJ, Morré DM. Medicinal benefits of green tea: Part II Review of anticancer properties. J Altern Complem Med 2005; 11:639-52. (Pubitemid 41279080)
6. Zhang M, Zhao X, Zhang X, Holman CD. Possible protective effect of green tea intake on risk of adult leukaemia. Br J Cancer 2008; 98:168-170.
7. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006; 108:804-11. (Pubitemid 44154611)
8. Sakaguchi S, Wing K, Miyara M. Regulatory T cells - a brief history and perspective. Eur J Immunol 2007; 37:S116-23. (Pubitemid 350131275)
9. Giannopoulos K, Schmitt M, Kowal M, Wlasiuk P, Bojarska-Junak A, Chen J, Rolinski J, Dmoszynska A. Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep 2008; 20:677-82.
10. D'Arena G, Laurenti L, Minervini MM, et al. Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. Leuk Res 2011; 35:363-68.
11. D'Arena G, D'Auria F, Simeon V, et al. A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia. Am J Hematol 2012; 87:628-31.
12. Lee YK, Bone ND, Strege AK, Shanafelt TD, Jelinek DF, Kay NE. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood 2004; 104:788-94. (Pubitemid 38970575)
13. Shanafelt TD, Lee YK, Call TG, Nowakowski GS, Dingli D, Zent CS, Kay NE. Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies. Leuk Res 2006; 30:707-12.
14. Shanafelt TD, Call TG, Zent CS, et al. Phase I trial of daily oral polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol 2009; 27:3808-14.
15. Shanafelt TD, Call TG, Zent CS, et al. Phase 2 trial of daily, oral polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Cancer 2013; 119(2):363-70.
16. Wong CP, Nguyen LP, Noh SK, Bray TM, Bruno RS, Ho E. Induction of regulatory T cells by green tea polyphenol EGCG. Immunol Letters 2011; 139:7-13.
17. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46:219-34.
18. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111:5446-56.
19. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25 high regulatory cells in human peripheral blood. J Immunol 2001; 167:1245-53. (Pubitemid 32703119)
20. Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ Treg cells. J Exp Med 2006; 203(7):1701-11. (Pubitemid 44036276)
21. Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006; 203(7):1693-00.
22. Tang Q, Blueston JA. The Foxp3 regulatory T cell: a jack of all trades, master of regulation. Nature Immunol 2008; 9:239-44. (Pubitemid 351267321)
23. Li MO, Flavell RA. Contextual regulation of inflammation: a duet by transforming growth factor beta and interleukin-10 Immunity 2008; 28:468-76.
24. Sabat R, Grutz G, Warszawska K, Kirsch S, Witte E, Wolk K, Geginat J. Biology of interleukin-10. Cytokine Growth F R 2010; 21:331-34.
25. Taylor A, Verhagen J, Blaser K, Akdis M, Akdis CA. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells. Immunology 2006; 117:433-42.
26. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: how do they suppress immune responses? Int Immunol 2009; 21:1105-11.
27. O'Brien S, Kay NE. Maintenance therapy for B-chronic lymphocytic leukemia. Clin Adv Res Hematol Oncol 2011; 9:22-1.
28. Hamblin T. Natural products and treatment of leukemia. Leuk Res 2006; 30:649-50.
29. Ben-Arye E, Attias S, Tamdor T, Schiff E. Herbs in hemato-oncological care: an evidence-based review of data on efficacy, safety, and drug interactions. Leuk Lymphoma 2010; 51(8):1414-23.
30. Miroddi M, Calapai F, Calapai G. Potential beneficial effects of garlic in oncohematology. Mini Rev Med Chem 2011; 11:461-72.
31. D'Arena G, Laurenti L, Coscia M, et al. Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey. Leuk Lymphoma (in press).